Clinical trial
A Study to Evaluate the Effect of HER2 Activation on rhuMAb 2C4 (Pertuzumab) in…
NCT00058552 · Genentech, Inc., Industry · Completed
Key facts
| NCT number | NCT00058552 |
|---|---|
| Title | A Study to Evaluate the Effect of HER2 Activation on rhuMAb 2C4 (Pertuzumab) in Subjects With Advanced Ovarian Cancer |
| Official title | A Phase II, Open-label, Multicenter Study to Evaluate the Effect of Tumor-based HER2 Activation on the Efficacy of rhuMAb 2C4 (Pertuzumab) in Subjects With Advanced, Refractory or Recurrent Ovarian Cancer |
| Lead sponsor | Genentech, Inc., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Ovarian Cancer |
| Intervention type | Drug |
| Interventions | Pertuzumab (rhuMAb 2C4) |
| Enrollment | 129 |
| Start date | May 1, 2003 |
| Primary completion | Jul 1, 2004 |
| Completion | Jul 1, 2004 |
| First posted | Apr 9, 2003 |
| Last update posted | Mar 8, 2017 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: